Clinical significance of matrix metalloproteinase (MMP)-2 in patients with acute heart failure

The serum levels of matrix metalloproteinases (MMPs) increase during chronic heart failure (HF) and the MMP-2 are related to a poor prognosis. However, the roles of MMP-2 in acute HF (AHF) remain unclear. We investigated the change and clinical significance of MMP-2 in these conditions. The serum levels of MMP-2 were measured in 83 AHF patients before starting treatment (day 1), 3 (day 3) and 7 (day 7) days after admission, and before discharge (predischarge). MMP-2 decreased rapidly and significantly from day 3 to day 1 (902.9 ± 304.2 versus 1220.4 ± 330.5 ng/mL; P < 0.0001), whereas that of MMP-2 was not significantly different on day 7 and at predischarge (894.7 ± 278.9 and 920.0 ± 269.6 ng/mL, respectively) compared to day 3. We evaluated the relationships between ΔMMPs, defined as the changes in MMPs from day 1 to day 3 and HF events including cardiac death, readmission to hospital for HF, and uncontrollable HF. The MMP-2 value was significantly (P = 0.004) more decreased in the event-free group (381.4 ± 256.5 ng/mL) than in the event group (211.9 ± 225.5 ng/mL) between day 1 and day 3. The results of the multivariate logistic regression model for predicting HF events found that the specific factor for HF events was ΔMMP-2. Cutoff values of ΔMMP-2 were determined and event-free curves were constructed. Kaplan-Meier curves showed that the prognosis was significantly better among the patients with reductions in ΔMMP-2 values of more than 342 ng/mL. The serum levels of MMP-2 decreased with improvements in AHF. Rapid decreases in MMP-2 may be important for a better clinical outcome in patients with AHF.     

Effect of lamivudine treatment on plasma levels of transforming growth factor β1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-t in patients with chronic hepatitis B

AIM: Transforming growth factor (TGF)-β1, metalloproteinase(MMP)-1 and its tissue inhibitor (TIMP)-1 are consideredpredictive biomarkers of chronic hepatitis activity and fibrosis. The aim of this study was to evaluate the effect of lamivudine treatment on the plasma levels of these peptides in patients with chronic hepatitis B.METHODS: TGF-β1, MMP-1 and TIMP-1 plasma concentrations were measured with an enzyme immunoassay in 40 patients treated with lamivudine for 48 wk. Elimination of HBV-DNAand HBV antigens was evaluated 24 wk after treatment completion.RESULTS: Baseline TGF-β1 (29.6±2.2 ng/mL) and TIMP-1(1 578±93 ng/mL) significantly exceeded normal values(18.3±1.6 ng/mL and 1 102±67 ng/mL respectively). Lamivudine treatment resulted in a significant decrease of TGF-β1 andTIMP-1 during treatment with an increase after 24 wk oftreatment. Pretreatment MMP-1 levels (6.7±0.7 ng/mL) weresignificantly lower than normal values (11.9±0.9 ng/mL) and increased during treatment and follow-up. A significant correlation was noted between TGF-β1 or TIMP-1 and aminotransferases as well as fibrosis scored in liver biopsy specimens. There were no statistically significant differences of TGF-β1, TIMP-1 and MMP-1 between four groups atbaseline, 24 and 48 wk of treatment. TGF-β1 and TIMP-1 levels increased significantly in non-responders and normalized in responders at wk 72. MMP-1 also normalized in responders and decreased to values significantly lower than normal innon-responders.CONCLUSION: These findings support the role of TGF-β1,TIMP-1 and MMP-1 in the pathogenesis of chronic hepatitis B.Because of their association with hepatic injury and antiviral treatment efficacy, determination of these peptides may be useful in disease management.     

经颈静脉肝内门体静脉分流术治疗乙型肝炎肝硬化门脉高压症患者疗效和血流动力学变化分析

目的 探讨采用经颈静脉肝内门体静脉分流术(TIPS)治疗乙型肝炎肝硬化并发门脉高压症(PHT)患者的疗效及其对血流动力学的影响。方法 2017年1月～2019年5月我院诊治的乙型肝炎肝硬化并发PHT患者96例,被随机分为两组,分组接受TIPS或腹腔镜下脾切除联合门奇静脉断流术治疗。采用ELISA法检测血清缺氧诱导因子-1α(HlF-1α)、金属基质蛋白酶2(MMP-2)和血管内皮生长因子(VEGF),使用彩色多普勒超声诊断系统检测门静脉直径(PVD)、门静脉血流流量(PVF)和门静脉血流流速(PVV)。结果 治疗后,TIPS组血清白蛋白水平为(36.3±3.6)g/L,血氨水平为(92.1±4.5) μmmol/L,显著高于开腹手术组【分别为(32.6±3.1)g/L和(54.2±5.6)μmmol/L, P<0.05】;PVV为(36.4±3.8)cm/s),显著快于开腹组【(32.5±3.1)cm/s),P<0.05】;血清HIF-α水平为(0.5±0.3)ng/mL,显著高于开腹组【(0.4±0.1)ng/mL,P<0.05】,而血清MMP-2和VEGF水平分别为(213.6±30.4)ng/mL和(92.3±9.7)ng/mL,显著低于开腹组【分别为(244.9±35.3)ng/mL和(112.4±12.8)ng/mL,P<0.05】;在术后6个月,TIPS组肝性脑病发生率为22.9%,显著高于开腹组的8.3%(P<0.05),而两组感染、再出血和肝功能稳定发生率无显著差异(P>0.05)。结论 采用TIPS术治疗乙型肝炎肝硬化并发PHT患者可改善门脉血流动力学参数,防止再出血,但有导致血氨升高和发生肝性脑病之虞,应该注意防治。     

血清脂联素水平与冠心病严重程度的关系

目的探讨血清脂联素（APN）水平与冠心病及其病变严重程度的相关性。方法选取135例行冠状动脉造影的患者,分别按Gensini积分、冠状动脉病变数目及临床诊断分组,进行血清APN测定。结果Gensini积分0分组（74.53±30.76ng/mL）和〈20分组（62.99±26.51ng/mL）APN水平分别显著高于20～40分组（44.06±15.18ng/mL）和〉40分组（28.96±11.87ng/mL）,P均〈0.01。20～40分组APN水平高于〉40分组（P〈0.05）。APN水平与Gensini积分的对数呈负相关（r=-0.556,P〈0.001）。对照组APN水平显著高于单支、双支和三支病变组（74.14±29.48ng/mL比55.29±23.40ng/mL、49.31±25.61ng/mL和38.39±15.57ng/mL,P均〈0.01）,单支病变组APN水平显著高于三支病变组（P〈0.01）。急性冠状动脉综合征组APN水平显著低于非冠心病组和稳定型心绞痛组（47.59±23.57ng/mL比67.05±31.53ng/mL、62.29±26.62ng/mL,P〈0.01和P〈0.05）。结论APN与冠状动脉狭窄程度、范围以及稳定性显著相关,有助于临床评价冠心病病变程度及其进展。     

C57黑鼠骨关节炎模型的关节病理积分与血清及滑膜中基质金属蛋白酶-3白细胞介素-1水平的相关性研究

目的 探讨基质金属蛋白酶(MMP)-3与白细胞介素(IL)-1在骨关节炎(OA)发病中所起的作用及其用于临床判断OA早期病理变化的可能性.方法 采用C57黑鼠OA模型.在自然增龄基础上,又对小鼠进行运动负荷训练.应用形态学方法对模型关节的病理切片观察,进行OA积分评分.研究采用酶联免疫吸附试验(ELISA)的方法.检测血清及滑膜中MMP-3、IL-1的水平.采用相关性分析来检验血清和滑膜中MMP-3、IL-1水平之间的关系,以及与OA积分评分之间的相关性.结果 ①形态学观察:C57黑鼠具有自发OA特征,其OA严重程度与周龄相关,且运动负荷可加快有自发OA倾向的小鼠关节软骨病理改变.②ELISA检测:运动负荷组滑膜中MMP-3[(84±6)ng/ml]、IL-1[(48±3)ng/ml]及血清中IL-1[(38.3±5.0 mg/ml]含量高于自然增龄组[滑膜MMP-3(71±5)ng,ml;IL-1(42±3)ng/ml;血清IL-1(8.1±2.4)ng/ml],差异有统计学意义(P<0.01);血清与滑膜中MMP-3、IL-1水平、OA评分存在线性相关[r均>0.67,P均<0.01].结论 联合检测MMP-3及IL-1在OA血清中的含量,有助于疾病的诊断与病情的判断.特别是MMP-3对于OA的早期诊断具有更为重要的意义.     

心肌桥合并冠状动脉粥样硬化患者的临床特点

目的探讨心肌桥合并冠状动脉粥样硬化患者的临床及冠脉造影特征。方法收集2005-2009年在我院经选择性冠状动脉造影证实的42例心肌桥患者的临床资料,根据造影结果将患者分为单纯性心肌桥组（19例）与心肌桥合并冠状动脉粥样硬化组（23例）,分析比较两组临床特点和造影结果。结果两组在性别及冠心病危险因素上差异无统计学意义,但心肌桥合并冠状动脉粥样硬化狭窄组存在2个或2个以上冠心病危险因素的概率要明显高于单纯心肌桥组。冠状动脉粥样硬化多发生于邻近心肌桥部位,其临床上多表现为急性冠脉综合征。结论心肌桥可能导致其邻近部位发生冠状动脉粥样硬化损伤并加速其进展。心肌桥合并冠状动脉粥样硬化患者可能发生更为严重的临床事件。     

不完全与完全心肌桥-壁冠状动脉的CT影像特征分析

目的 对比评价不完全与完全心肌桥-壁冠状动脉(MB-MCA)的CT影像学特征.方法 回顾性分析50例显示有MB患者的双源CT冠状动脉血管成像(DSCTA)资料,将其分为不完全MB-MCA组(MCA被心肌部分包绕,至少在1/2以上)和完全MB-MCA组(MCA完全被心肌包绕),分别在其最佳收缩期及舒张期测量MCA及其近远侧血管的管径变化,计算MCA狭窄率,并记录MB近侧血管发生粥样硬化情况.结果 50例患者中,DSCTA显示58处MB,平均长度为(2.02±1.02)cm,其中不完全MB 23处,完全MB 35处,前降支中段32处(55.2%),前降支远段17处(29.3%),前降支近段1处,第一对角支3处,钝缘支4处,右冠状动脉远段1处.不完全MB-MCA舒张期及收缩期管径、狭窄率分别为(1.93±0.49)mm、(1.71±0.45)mm和25.21%±21.02%,完全MB-MCA舒张期及收缩期管径、狭窄率分别为(2.21±0.41)mm、(1.63±0.52)mm和10.38%±20.2%.两型MB-MCA管径变化(t=2.76,P=0.008)及MCA狭窄率(t=2.667,P=0.01)差异有统计学意义.8处(34.78%)不完全MB及15处(42.86%)完全MB近侧血管发生粥样硬化,两者之间差异无统计学意义(x2=0.378,P＞0.05).结论 DSCTA能够清晰的显示不完全和完全MB,并能准确评价MB-MCA在舒张期和收缩期的形态学变化及MB近侧血管发生粥样硬化的情况.

Abstract：

Objective To evaluate the CT imaging characteristics of incomplete and complete myocardial bridges-mural coronary artery(MB-MCA). Methods Fifty subjects with dual source coronary CT angiography(DSCTA)evidenced MB were included. The subjects were divided into incomplete MBMCA and complete MB-MCA groups. The diameter of MCA in best systole phase and diastole phase, the MCA stenosis rate, the presence of atheromatous change proximal to the MB were evaluated. Results There were 58 MB, the average length was(2. 02 ± 1.02)cm, 23 were incomplete MB and 35 were complete MB.Thirty-two MB were in the middle segments of left anterior descending artery(55.2%);17 MB were in the distal segment of the left anterior descending artery(29. 3%);1 MB was in the proximal segment of left anterior descending artery;3 MB in diagonal branch;4 MB in obtuse marginal branch, 1 MB in distal right coronary artery. It was statistically significant difference between the incomplete MB-MCA and the complete MB-MCA of the diameter change in diastole and systole phase[(1.93 ±0. 49)mm,(1.71 ±0. 45)mm vs.(2.21 ±0.41)mm,(1.63 ±0.52)mm, P=0.008]and stenosis rate(10.38%±20.2%vs. 25.12% ±21.02%, P = 0. 01). Atherosclerotic finding was evidenced in 8 incomplete MB(34. 78%)and 15complete MB(42. 86%)at the proximal vessel of mural coronary artery(P ＞ 0. 05). Conclusion DSCTA can vividly display the incomplete and complete myocardial MB, accurately evaluate the shape change of MB-MCA in diastole and systole phase and detect the atherosclerotic change in the proximal vessel of MB.     

急性冠状动脉综合征患者支架植入术后再狭窄与基质金属蛋白酶相关性的研究

目的 测定急性冠状动脉综合征(ACS)支架植入术后再狭窄患者动脉血基质金属蛋白酶(MMP)-3、-9及其组织抑制剂TIMI-1水平变化,初步分析支架内再狭窄与基质金属蛋白酶水平之间可能存在的相关性. 方法 132例ACS患者,分别收集其冠状动脉内支架植入术前和术后即刻、8、48 h和1周的股动脉血标本,采用酶联免疫吸附试验(ELISA)法检测MMP-3、MMP-9和TIMI-1水平;随访5～10个月后行冠状动脉造影,根据造影结果分为再狭窄组21例,非再狭窄组111例,均于造影术前股动脉采集动脉血标本重复指标测定.50例冠状动脉造影正常者为对照组. 结果 与对照组比较,ACS组动脉血MMP-3和MMP-9浓度明显升高[MMP-3:(15.99±4.30)ng/L与(4.86±2.98)ng/L,t=2.290,P=0.022;MMP-9:(1.41±3.06)ng/L与(3.79±1.46)ng/L,t=2.011,P=0.041],TIMP-1浓度有升高趋势.支架植入术后MMP-3和MMP-9水平均较术前明显升高,48 h达到高峰,1周时仍明显升高,TIMP-1水平也具有类似的变化,但高峰时间延迟.再狭窄组术前MMP-9水平较非再狭窄组升高[(17.94±6.44)ng/L与(9.93±2.19)ng/L,t=3.180,P=0.003],而两组间术前MMP-3和TIMP-1水平差异无统计学意义;随访时再狭窄组MMP-3和MMP-9水平均较非再狭窄组明显升高[MMP-3:(21.66±2.72)ng/L与(14.27±1.28)ng/L,t=2.181,P=0.033;MMP-9:(22.81±5.31)ng/L与(12.10±2.76)ng/L,t=2.108,P=0.039],而TIMP-1水平差异无统计学意义. 结论 动脉血MMP-3和MMP-9水平升高可能参与了ACS患者支架置入术后的病理、生理过程,并可能与术后再狭窄的发生有一定相关性.     

Role of soluble intercellular adhesion molecule-1 in the process of peritonitis in peritoneal dialysis

ObjectiveTo investigate the role and clinical significance of changes of levels of soluble intercellular adhesion molecule-1 in the process of peritonitis in peritoneal dialysis patients.MethodsA total of 50 patients on continuous ambulatory peritoneal dialysis in the Shanghai Changhai Hospital between May 1999 and July 2000 were enrolled into this study. They were assigned to two groups according to diagnostic standard of peritonitis-Group A, with episodes of peritonitis; Group B, in the absence of peritonitis. The serum and peritoneal effluent levels of soluble intercellular adhesion molecule-1 during and after peritonitis were assessed by using sandwiched enzyme-linked immunosorbent assay.ResultsThe serum levels of soluble intercellular adhesion molecule-1 in Group A were significantly lower compared with Group B (214.5 ± 90.7 vs 511.2 ± 124.7 ng/mL; p<0.01). The peritoneal effluent levels of soluble intercellular adhesion molecule-1 in Group A were significantly higher than those in Group B (5.8 ± 1.6 vs 2.1 ± 0.9 ng/mL; p<0.01). For Group A, after treatment of peritonitis, the serum levels of soluble intercellular adhesion molecule-1 profoundly increased to 506.1 ± 107.8 ng/mL and the peritoneal effluent levels of soluble intercellular adhesion molecule-1 markedly decreased to 3.9 ± 1.1 ng/mL, compared with those during peritonitis, respectively (p<0.01).ConclusionThe study showed that increased peritoneal effluent levels of soluble intercellular adhesion molecule-1 during peritonitis possibly activate or damage peritoneal mesothelial cells. Monitoring changes of levels of soluble intercellular adhesion molecule-1 in peritoneal dialysis fluid may be useful for analyzing the process of peritonitis.     

慢加急性乙型肝炎肝衰竭患者血清自噬相关蛋白水平及其临床意义探讨*

目的 探讨慢加急性乙型肝炎肝衰竭(HBV-ACLF)患者血清p62、微管相关蛋白1轻链3-Ⅱ(LC3-Ⅱ)和Beclin1水平变化及其临床意义。方法 2018年9月～2020年9月我院收治的HBV-ACLF患者60例和同期体检的健康人65例,计算终末期肝病模型评分(MELD),采用ELISA法测定血清p62、Beclin1和LC3-Ⅱ水平;应用受试者工作特征曲线(ROC)下面积(AUC)评估指标对HBV-ACLF患者预后的预测效能。结果 60例HBV-ACLF患者血清LC3-Ⅱ和Beclin1水平分别为(66.8±13.5)ng/mL和(11.7±3.6)ng/mL,均显著高于健康人【分别为(35.8±6.2)ng/mL和(8.2±2.9)ng/mL,P＜0.05】,而血清p62水平为(2.5±0.9)ng/mL,显著低于健康人【(4.5±1.6)ng/mL,P＜0.05】;在治疗观察90 d,本组HBV-ACLF患者死亡18例(30.0%);入院时死亡组血清LC3-Ⅱ、Beclin1和MELD评分为(76.25±12.1)ng/mL、(10.9±3.2)ng/mL和(20.1±3.3)分,均显著高于生存组【分别为(62.8±10.2)ng/mL、(13.4±3.5)ng/mL和(16.7±4.6)分,P＜0.05】,而血清p62水平为(1.7±0.6)ng/mL,显著低于生存组【(2.9±0.8)ng/mL,P＜0.05】;ROC曲线分析发现,以血清p62＜2.2 ng/mL、LC3-Ⅱ＞70.3 ng/mL和Beclin1＞12.6 ng/mL为截断点,预测HBV-ACLF患者预后不良的AUC分别为0.856、0.820和0.765,三者联合预测的AUC为0.910,与以MELD评分＞18.3 分为截断点的预测效能为0.917相差无几。结论 应用血清p62、LC3-Ⅱ和Beclin1水平预测HBV-ACLF患者预后有一定的实用意义,值得进一步动态观察。     

姜黄素对不稳定型心绞痛患者血清明胶酶水平的影响

目的：探讨姜黄素对不稳定型心绞痛患者血清明胶酶水平的影响。方法：选择2010年1月至2010年9月住院的不稳定型心绞痛患者共80例,随机分为常规治疗对照组（n=40）和姜黄素治疗组（n=40）,分别测定两组治疗前及治疗30d后血清明胶酶[包括基质金属蛋白酶-2（MMP-2）和MMP-9]的水平。结果：与治疗前比较,姜黄素治疗组治疗后血清明胶酶水平明显下降[MMP-2：（52.64±6.77）ng/ml：（32.65±1.67）ng/ml,MMP-9：（56.75±7.34）ng/ml：（35±1.88）ng/ml],P〈0.01。姜黄素治疗组治疗后血清明胶酶水平明显低于常规治疗对照组治疗后[MMP-2：（32.65±1.67）ng/ml：（37.78±2.76）ng/ml,MMP-9：（35±1.88）ng/ml：（40.23±1.95）ng/ml],P〈0.05。结论：姜黄素能降低不稳定型心绞痛患者血清明胶酶水平,起到稳定粥样斑块的作用。     

Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction

OBJECTIVES: The importance of matrix metalloproteinases (MMPs) in the progression and rupture of the atherosclerotic plaque is gaining increasing recognition but the mechanisms are not yet fully understood. The aim of this study was to investigate the significance of MMP-3 in the acute phase of myocardial infarction (MI) and the influence of the -1612 5A/6A MMP-3 gene promoter polymorphism on serum MMP-3 concentration. SUBJECTS: One-hundred and sixty-four patients admitted with ST-elevation MI and receiving thrombolysis treatment were included in this study. Serum MMP-3 was analysed at admission, after 48 h and at 3 months. RESULTS: Serum MMP-3 concentration was significantly increased at 3 months when compared with admission and 48 h (19.5 ng mL(-1) [14.4-24.7] vs. 15.5 ng mL(-1) [10.5-21.8] at admission, P < 0.001; and 14.7 ng mL(-1) [9.9-23.8] at 48 h, P < 0.001). Furthermore, we found the -1612 5A/6A polymorphism to influence the serum concentration of MMP-3 at all time-points: 14.1 ng mL(-1) [10.2-18.8] in 5A/5A; 19.6 ng mL(-1) [15.0-24.4] in 5A/6A; and 24.0 ng mL(-1) [20.1-32.3] in 6A/6A genotype at 3 months (P < 0.001 between all groups). Female patients had lower serum MMP-3 concentration than male patients at all time-points (14.8 ng mL(-1) [9.4-20.8] vs. 19.9 ng mL(-1) [16.0-26.9], P < 0.0001 at 3 months). CONCLUSIONS: Serum concentration of MMP-3 is significantly lower in the acute stage of MI than during recovery and is significantly influenced by -1612 5A/6A genotype and gender. Together with previous findings, these results primarily implicate MMP-3 in atherosclerosis progression rather than in acute MI.     

冠状动脉介入治疗对肿瘤坏死因子a和基质金属蛋白酶-9水平的影响

目的观察经冠状动脉介入治疗（PCI）治疗对肿瘤坏死因子α（TNF-α）及基质金属蛋白酶-9（MMP-9）的影响。方法纳入存在单支病变经PCI治疗的冠心病患者60例,同期经冠状动脉造影证实冠状动脉正常者30例作为对照组。分析两组冠心病危险因素的合并比例,采用酶联免疫吸附法分别检测入选患者冠状动脉介入治疗前后TNF-α和MMP-9水平并进行组间比较。结果①有冠状动脉狭窄需行PCI治疗患者存在冠心病危险因素的比例高于对照组;②PCI组患者术后血浆TNF-α显著高于术前[（19.89±5.41）ng/mLvs.（15.78±5.34）ng/ml,P〈0.01],对照组冠状动脉造影术后TNF-α与术前相比差异无统计学意义[（13.76±5.54）ng/mLvs.（12.48±5.12）ng/mL,P〉0.05];③PCI组患者术后血浆MMP-9显著高于术前[（21.97±5.93）mg/Lvs.（18.65±5.72）mg/L,P〈0.01],对照组冠脉造影术后MMP-9与术前相比差异无统计学意义[（16.21±5.33）mg/Lvs.（15.31±5.21）mg/L,P〉0.05]。结论需PCI治疗的患者冠心病危险因素高于无冠脉狭窄者,冠脉介入治疗较冠脉造影可造成冠心病患者血浆TNF-α及MMP-9水平明显升高,可能与术后支架再狭窄有关。     

Usefulness of serum tryptase level as an independent biomarker for coronary plaque instability in a Chinese population

Tryptase and chymase are unique mast cell proteases that are essential in atherogenesis. This study establishes a link between serum tryptase and chymase levels and human coronary heart diseases (CHD) in a cohort of 270 subjects. Serum tryptase levels were significantly higher in patients with substantial CHD than in those without substantial CHD (substantial CHD vs. unsubstantial CHD: 7.81 ± 0.52 ng/mL vs. 6.11 ± 0.51 ng/mL, P=0.002). After subgrouping the substantial CHD patients into those with acute myocardial infarction (AMI) and those with unstable or stable angina pectoris (UAP or SAP), we demonstrated that serum tryptase levels were nearly doubled in AMI patients as compared with unsubstantial CHD patients (11.13 ± 1.55 ng/mL vs. 6.11 ± 0.51 ng/mL, P<0.01), and significantly higher than in UAP patients (7.19 ± 0.62 ng/mL, P<0.05) or SAP patients (6.80 ± 0.94 ng/mL, P<0.05). Although Spearman's correlation test showed that serum tryptase correlated significantly with age (P=0.014) and weakly with fasting glucose (P=0.084), total cholesterol (P=0.071), low-density lipoprotein (P=0.063), and triglyceride (P=0.058), serum tryptase levels remained significantly higher in substantial CHD patients than in unsubstantial CHD patients in a multiple linear regression test after adjusting for all these confounders (P=0.008). Serum chymase levels were also higher in AMI patients (27.64 ± 7.57 ng/mL) or UAP patients (24.62 ± 8.06 ng/mL) than in SAP patients (15.20 ± 0.81 ng/mL) or unsubstantial CHD patients (16.84 ± 0.56 ng/mL), although such differences were not statistically significant. Spearman's correlation test revealed that serum chymase levels correlated significantly only with fasting glucose levels (P=0.019), and CHD status did not affect chymase levels before and after adjusting for all confounders. Our observations suggest that serum tryptase is an independent biomarker for coronary plaque stability in this Chinese population.     

腹腔镜胆囊切除术治疗胆囊结石伴慢性胆囊炎患者治疗效果分析

目的 探讨采用腹腔镜胆囊切除术(LC)治疗胆囊结石伴慢性胆囊炎患者的治疗效果及血清胃泌素(GAS)、胃动素(MOT)和血管活性肠肽(VIP)水平的变化.方法 2018年3月 ～2020年3月我院普外科就诊的70例胆囊结石伴慢性胆囊炎患者,采用随机数字表法将患者分为对照组35例和观察组35例,分别行小切口胆囊切除术或行L...     

丹栀逍遥散对D-氨基半乳糖/脂多糖诱导的大鼠急性肝损伤保护作用机制研究

目的 探讨丹栀逍遥散对D-氨基半乳糖(D-GaIN)/脂多糖(LPS)诱导的大鼠急性肝损伤(ALI)的保护作用及其可能的作用机制.方法 将110只SD大鼠随机分为对照组、模型组、小剂量、中剂量和大剂量丹栀逍遥散干预组,每组22只.采用D-GaIN)/LPS腹腔注射建立ALI模型,分别给予生理盐水或药物灌胃干预.采用EL...     

中期因子对大鼠急性心肌梗死后心室重构和基质金属蛋白酶9水平的影响

目的探讨中期因子(MK)对大鼠急性心肌梗死(AMI)后心室重构及血清基质金属蛋白酶9(MMP-9)水平的影响。方法雄性Wistar大鼠60只采用随机数字抽样法分为4组,每组15只:空白组(Control组),伪手术组(Sham组),AMI组,MK治疗组(MK组)。结扎大鼠左冠状动脉前降支制作AMI模型,模型建立成功后,MK组立即给予MK心肌注射。4周后,取各组剩余大鼠称重,测血流动力学指标;ELISA法测定血清MMP-9水平;心脏称重,计算心体比;取心尖部分切片,一部分MASSON染色,测定左心室游离壁梗死区厚度、长度和梗死面积,心肌梗死区及非梗死区胶原容积分数(CVF),另一部分HE染色,观察毛细血管生成情况。结果 A MI组较Control组和Sham组心室重构和心功能受损明显(P<0.05),血清MMP-9水平明显升高[(6.93±0.09)ng/ml比(4.66±0.06)ng/ml和(4.71±0.06)ng/ml,均为P<0.05];MK组较AMI组心室重构程度轻、心功能改善明显(P<0.05),血清MMP-9水平明显降低[(5.33±0.06)ng/ml比(6.93±0.09)ng/ml,P<0.05 ]。结论 AMI后立即给予MK能够有效抑制心室重构,改善心功能;降低血清MMP-9水平是MK发挥心肌保护作用的途径之一。     

自身免疫性肝炎患者血清趋化因子和GP73水平变化及其临床意义研究

目的 探讨自身免疫性肝炎(AIH)患者血清趋化因子和高尔基体糖蛋白73(GP73)水平的变化及其临床意义。方法 2018年3月～2019年3月我院就诊的46例自身免疫性肝炎患者和46例同期健康人群,采用ELIS法检测血清趋化因子C-C-基元受体6和20(CCR6、CCL20)、血清趋化因子配体10(CXCL10)和GP73水平。AIH患者接受肝活检,并将肝炎程度分为轻中重度。结果 AIH血清CCR6、CCL20、CXCL10和GP73水平分别为(112.4±59.3)pg/mL、(186.5±71.8)pg/mL、(81.5±42.0)pg/mL和(171.4±62.5)ng/mL,均显著高于健康人【分别为(75.8±32.6)pg/mL、(123.7±42.2)pg/mL、(53.9±28.1)pg/mL和(83.1±35.2)ng/mL,P<0.05】;10例重度患者血清CCR6、CCL20、CXCL10和GP73水平分别为(174.2±81.4)pg/mL、(271.5±99.7)pg/mL、(162.7±83.1)pg/mL和(278.3±91.5)ng/mL,,显著高于14例中度组【分别为(124.5±55.3)pg/mL、(198.6±66.9)pg/mL、(88.4±46.8)pg/mL和(186.2±75.8)ng/mL,P<0.05】或22例轻度组【分别为(83.5±34.5)pg/mL、(155.6±51.0)pg/mL、(42.6±22.7)pg/mL和(123.9±58.9)ng/mL,P<0.05】;26例肝组织G3～4级患者血清CCR6、CCL20、CXCL10和GP73水平分别为(154.5±28.1)pg/mL、(201.6±56.3)pg/mL、(98.4±56.1)pg/mL和(196.2±59.78)ng/mL,显著高于20例G1～2级组【分别为(73.5±34.8)pg/mL、(135.6±41.7)pg/mL、(62.5±20.1)p g/mL和(93.9±33.9)ng/mL,P<0.05】。结论 AIH患者血清CCR6、CCL20、CXCL10和GP73水平升高,且随着疾病程度和肝组织炎症活动度加重而升高。检测自身免疫性肝炎患者血清趋化因子和GP73水平可能有助于评估患者病情的变化。     

孟鲁司特钠治疗慢性阻塞性肺疾病122例临床疗效观察

目的 探讨孟鲁司特钠治疗COPD的临床疗效.方法 将122例COPD患者随机分为对照组和观察组,各61例.对照组采用抗感染、氧疗、祛痰、支气管舒张剂等常规治疗,观察组在对照组的基础上加用孟鲁司特钠10 mg,每晚睡前服用,疗程为4周.测定和分析治疗前和治疗4周后患者的肺功能、血气分析指标.ELISA法检测血清细胞因子肿瘤坏死因子α(TNF-α)、IL-8及基质金属蛋白酶9(MMP-9)的水平,并对治疗4周后2组临床疗效进行比较.结果 治疗前2组患者的肺功能(FEV1％pred、FEV1/FVC、MVV％ pred),血气分析(PaO2、PaCO2)及血清细胞因子(TNF-α、IL-8,MMP-9)的差异无统计学意义(P＞0.05).治疗4周后,FEV1％pred[(80.3±15.8)％ vs (71.3±18.5)％],FEV1/FVC[(86.2±9.8)％ vs (67.3±16.6)％],MVV％pred[(49.3±13.9)％ vs(42.1±12.3)％]和PaO2[(83.3±4.9) mmHg vs (76.1±4.5) mmHg]观察组明显高于对照组.PaCO2[(53.3±6.23) mmHg vs (61.3±5.32) mmHg],血清细胞因子TNF-α[(25.2±6.3) ng/L vs (33.1±8.5) ng/L],IL-8[(53.6±11.5) ng/L vs (66.5±13.1) ng/L]及MMP-9[(38.9±12.3) ng/L vs (46.6±13.2) ng/L]观察组的含量明显低于对照.观察组的总有效率(96.72％)明显高于对照组的总有效率(86.89％),2组比较差异有统计学意义(P ＜0.05).结论 孟鲁司特钠能有效减轻COPD患者的炎症症状,改善肺功能,疗效显著,值得在临床上推广.     

肝细胞癌患者血清HSP90α和PIVKA-Ⅱ水平变化及其临床意义探讨*

目的 探讨热休克蛋白90α(HSP90α)和维生素K拮抗剂诱导蛋白-Ⅱ(PIVKA-Ⅱ)在肝细胞癌(HCC)患者血清变化及在预后评估中的价值。方法 2014年1月～2016年6月我院诊治的HCC患者112例、乙型肝炎肝硬化患者96例、慢性乙型肝炎患者82例和健康体检者84例,所有肝癌患者接受经肝动脉化疗栓塞术,采用ELISA法检测血清HSP90α和PIVKA-Ⅱ水平,采用多元Logistic回归分析影响3 a生存的因素,应用ROC曲线评估血清HSP90α和PIVKA-Ⅱ单独或联合预测HCC患者3 a生存率的价值。结果 HCC组血清HSP90α和PIVKA-Ⅱ水平分别为(61.6±5.0)ng/mL和(832.6±66.7)mAU/mL,显著高于乙型肝炎肝硬化组[分别为(13.2±1.6)ng/mL和(29.4±2.9)mAU/mL,P<0.05]、慢性乙型肝炎组[分别为(4.3±0.4)ng/mL和(29.1±3.0)mAU/mL,P<0.05]或健康人组[分别为(3.2±0.4)ng/mL和(26.7±3.2)mAU/mL,P<0.05];入组时55例生存组血清HSP90α和PIVKA-Ⅱ水平分别为(44.4±4.4)ng/mL和(701.3±62.3)mAU/mL,显著低于57例死亡组[分别为(78.3±5.2)ng/mL和(959.2±92.2)mAU/mL,P<0.05];单因素分析表明肝外转移、肿瘤分化程度、Child-Pugh分级、TNM分期、血清HSP90α和PIVKA-Ⅱ水平影响HCC患者生存,而多因素Logistic回归分析发现,肝外转移、肿瘤分化程度低、Child-Pugh C级、TNM Ⅲ~Ⅳ期、血清HSP90α和PIVKA-Ⅱ水平高为影响HCC患者3 a生存率的独立危险因素(P<0.05);ROC曲线分析结果显示血清HSP90α和PIVKA-Ⅱ单独预测HCC患者3 a生存率的AUC分别为0.814和0.836,显著低于两者联合预测的0.929(P<0.05)。结论 血清HSP90α和PIVKA-Ⅱ水平影响肝细胞癌患者生存,对于高水平者,应密切观察其病情变化,并及时给予适当的干预。